- Home
- AGIO vs KNSA Comparison
AGIO vs KNSA Comparison
Compare AGIO & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- KNSA
- Stock Information
- Founded
- AGIO 2007
- KNSA 2015
- Country
- AGIO United States
- KNSA United Kingdom
- Employees
- AGIO N/A
- KNSA N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- AGIO Health Care
- KNSA Health Care
- Exchange
- AGIO Nasdaq
- KNSA Nasdaq
- Market Cap
- AGIO 2.3B
- KNSA 2.6B
- IPO Year
- AGIO 2013
- KNSA 2018
- Fundamental
- Price
- AGIO $36.78
- KNSA $37.10
- Analyst Decision
- AGIO Buy
- KNSA Strong Buy
- Analyst Count
- AGIO 6
- KNSA 6
- Target Price
- AGIO $57.00
- KNSA $40.83
- AVG Volume (30 Days)
- AGIO 779.8K
- KNSA 431.3K
- Earning Date
- AGIO 10-30-2025
- KNSA 10-28-2025
- Dividend Yield
- AGIO N/A
- KNSA N/A
- EPS Growth
- AGIO N/A
- KNSA N/A
- EPS
- AGIO 11.13
- KNSA 0.07
- Revenue
- AGIO $40,875,000.00
- KNSA $529,332,000.00
- Revenue This Year
- AGIO $28.19
- KNSA $37.21
- Revenue Next Year
- AGIO $152.14
- KNSA $11.99
- P/E Ratio
- AGIO $3.31
- KNSA $573.99
- Revenue Growth
- AGIO 30.57
- KNSA 56.18
- 52 Week Low
- AGIO $23.42
- KNSA $17.82
- 52 Week High
- AGIO $62.58
- KNSA $37.34
- Technical
- Relative Strength Index (RSI)
- AGIO 48.43
- KNSA 73.54
- Support Level
- AGIO $34.97
- KNSA $35.72
- Resistance Level
- AGIO $37.91
- KNSA $37.25
- Average True Range (ATR)
- AGIO 1.67
- KNSA 0.95
- MACD
- AGIO -0.21
- KNSA 0.14
- Stochastic Oscillator
- AGIO 48.57
- KNSA 94.82
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.